Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-03-07 Environmental & Social …
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Environmental & Social Information Classification · 99% confidence The document is a press release from argenx announcing that clinical trial and real-world data for their products (VYVGART and VYVGART Hytrulo) will be presented at the American Academy of Neurology (AAN) Annual Meeting. It details the specific presentations (oral and poster) and highlights key findings. This type of announcement, which publicizes upcoming scientific presentations or data disclosures, is characteristic of an Investor Presentation (IP) or a general press release about scientific progress. Since it is not a formal regulatory filing (like 10-K or IR), nor is it a transcript (CT) or a management discussion (MDA), the most fitting category for a detailed presentation of clinical data intended for investors and the scientific community is 'Investor Presentation' (IP). Although it is an announcement, the content is substantial and focuses on scientific data presentation rather than just announcing the publication of a report (which would be RPA/RNS). Given the focus on clinical data and scientific engagement, IP is the best fit.
2025-03-07 English
6-K
Regulatory Filings
2025-02-27 English
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Earnings Release Classification · 100% confidence The document is a press release from argenx reporting their full-year 2024 financial results and business update. It includes key financial highlights, management commentary, pipeline updates, and condensed financial statements. While it contains financial data, it is an initial announcement of results rather than a full 10-K or audited annual report. According to the filing definitions, this fits the 'Earnings Release' (ER) category as it provides the initial announcement of quarterly/periodical financial results and key highlights. FY 2024
2025-02-27 English
argenx to Present at TD Cowen 45th Annual Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a short announcement (1621 characters) notifying the public that the CEO of argenx will be presenting at an upcoming healthcare conference. It provides details on the date, time, and how to access the webcast. It does not contain the actual presentation slides or financial data, but rather serves as an announcement of an upcoming event. Under the 'Menu vs Meal' rule, this is a regulatory announcement regarding an event, which fits best under the RNS category as it is a general regulatory announcement that does not fit into more specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Report Publication Announcement'.
2025-02-25 English
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
Report Publication Announcement Classification · 95% confidence The document is a short announcement (under 2,000 characters) informing stakeholders about the upcoming date and time for an earnings conference call and the release of financial results. It does not contain the actual financial results or the transcript of the call, but rather serves as a notification of the event. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-02-20 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.